Quadrant Capital Group LLC Fate Therapeutics Inc Transaction History
Quadrant Capital Group LLC
- $1.42 Billion
- Q3 2024
A detailed history of Quadrant Capital Group LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 349 shares of FATE stock, worth $725. This represents 0.0% of its overall portfolio holdings.
Number of Shares
349
Previous 268
30.22%
Holding current value
$725
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding FATE
# of Institutions
174Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$27.4 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$21.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$21 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$11.6 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$10.9 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $202M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...